Author: Marty, Francisco M; Chemaly, Roy F; Mullane, Kathleen M; Lee, Dong-Gun; Hirsch, Hans H; Small, Catherine B; Bergeron, Anne; Shoham, Shmuel; Ljungman, Per; Waghmare, Alpana; Blanchard, Elodie; Kim, Yae-Jean; McKevitt, Matt; Porter, Danielle P; Jordan, Robert; Guo, Ying; German, Polina; Boeckh, Michael; Watkins, Timothy R; Chien, Jason W; Dadwal, Sanjeet S
Title: A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract Document date: 2019_12_3
ID: sl45z4i0_31
Snippet: This is the first placebo-controlled clinical trial, to our knowledge, evaluating treatment of RSV LRTI with a new antiviral agent in HCT recipients. Presatovir had a favorable safety profile and was well tolerated but did not decrease timeweighted average change in nasal RSV viral load from day 1 to day 9, number of days with supplemental oxygen use, or frequency of respiratory failure or mortality relative to placebo. In contrast, presatovir tr.....
Document: This is the first placebo-controlled clinical trial, to our knowledge, evaluating treatment of RSV LRTI with a new antiviral agent in HCT recipients. Presatovir had a favorable safety profile and was well tolerated but did not decrease timeweighted average change in nasal RSV viral load from day 1 to day 9, number of days with supplemental oxygen use, or frequency of respiratory failure or mortality relative to placebo. In contrast, presatovir treatment significantly reduced viral load, clinical signs, and symptoms of experimental RSV infection in healthy volunteers treated upon detection of RSV replication [16] . Potential explanations for this discrepancy have important implications for design of clinical trials evaluating antiviral treatments for RSV infection in HCT recipients and other patient populations.
Search related documents:
Co phrase search for related documents- antiviral agent and healthy volunteer: 1
- antiviral agent and mortality respiratory failure: 1, 2
- antiviral agent and respiratory failure: 1, 2, 3, 4, 5, 6
- antiviral agent and RSV infection: 1, 2, 3, 4
- antiviral agent and RSV replication: 1
- antiviral agent and safety profile: 1, 2, 3, 4, 5, 6, 7, 8, 9
- antiviral agent and viral load: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- antiviral treatment and clinical sign: 1
- antiviral treatment and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59
- antiviral treatment and clinical trial design: 1, 2, 3, 4
- antiviral treatment and day number: 1, 2, 3, 4
- antiviral treatment and favorable safety profile: 1, 2
- antiviral treatment and healthy volunteer: 1
- antiviral treatment and important implication: 1
- antiviral treatment and mortality respiratory failure: 1, 2, 3, 4
- antiviral treatment and patient population: 1, 2
- antiviral treatment and placebo control: 1, 2, 3, 4
- antiviral treatment and presatovir treatment: 1
- antiviral treatment and respiratory failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64
Co phrase search for related documents, hyperlinks ordered by date